Navigation Links
Synvista Therapeutics Posts Letter to Stockholders on Web Site
Date:9/17/2008

on track for completion in late 2009.

We have met with the FDA on these two studies and believe that our clinical endpoints are acceptable to them.

While we decided not to pursue the development of SYI-2074 in heart disease, we believe that the compound has characteristics that may make it a compelling treatment for psoriasis. We completed the formulation development for topical SYI-2074 in the third quarter of 2008, and we expect to begin patient enrollment in a 30-patient Phase 2 study in this area in October 2008.

We also have developed a new family of glutathione peroxidase mimetics with properties that may be more attractive than SYI-2074 in treating heart disease. We have selected the lead compound and have begun preclinical testing. We have shown that our new family of compounds can attenuate the loss of cholesterol efflux seen in select patients with diabetes. Higher levels of cholesterol efflux may correlate with reduced atherosclerosis.

LEADERSHIP

We welcomed several important additions to the Synvista management team in the past year. Carl Mendel, M.D., was appointed to the position of Vice President, Clinical Development and Chief Medical Officer and is responsible for the clinical-stage development of the Company's lead products. Dr. Mendel brings 15 years of experience in the pharmaceutical industry, successfully directing development programs in metabolism, obesity, cardiovascular disease, abuse potential, oncology, virology and other therapeutic areas. David C. Tantillo joined us as Senior Director, Marketing and Sales, a newly created position and brings to Synvista nearly 20 years of broad-based industry experience. Mr. Tantillo is responsible for planning and implementing commercialization of the Company's haptoglobin diagnostic test.

We strengthened our board of directors with the appointment of John F. Bedard, expanding our board to four members. Mr. Bedard brings 25 years of highly relevant experience,
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
2. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
3. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
4. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
5. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
6. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
7. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
8. Synvista Therapeutics to be Featured on Wallst.net
9. Synvista Therapeutics to Present at the BIO InvestorForum 2007
10. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar will ... and clinical safety assessment in biosimilars. , Regulatory frameworks ... biosimilar drug development, however the complex nature of biopharmaceuticals ... safety and efficacy extremely challenging. Based on the specific ...
(Date:1/15/2014)... 2014 DTS Language Services, Inc . ... Portal for Life Science organizations who need document translations. ... matter of their documents in advance with a selection of ... of translations, often a critical factor in clinical and scientific ...
(Date:1/14/2014)... 14, 2014 Date: Friday, April 11, 2014 ... Country Club, 1360 Almshouse Road, Warrington, Pa. , ... solely dedicated to finding a cure for hepatitis B and ... host its annual Crystal Ball on Friday, April 11 at ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Published by Medical Marketing & Media, CARY, ... in behavioral science-based relationship marketing, is ranked one ... Marketing & Media,s annual,"Agency Issue" review, published this ... for 2007, place MicroMass,among some of the largest ...
... avoid costly and potentially embarrassing mistakes when ... seems that every month there,is a news story questioning the ... controversy has been in the news. The,truth is, no matter ... used,for, mistakes are easy to make and difficult to recognize ...
... Group Purchasing Organizations Hosted,by Trane -, NATIONAL ... of,Healthcare Engineering (ASHE) offers professional learning opportunities,for its ... no exception. Added,to the roster for the first ... comfort systems and comprehensive facility solutions., Leaders ...
Cached Biology Technology:North Carolina Marketing Firm MicroMass Named One of Top 60 Healthcare Agencies in U.S. 2QualityMetric Announces QM Certified Scoring Program 2Healthcare Facility Managers Learn to Optimize Surgical Suites at 2008 ASHE Annual Conference 2Healthcare Facility Managers Learn to Optimize Surgical Suites at 2008 ASHE Annual Conference 3
(Date:4/17/2014)... have uncovered a new way the immune system may ... efforts to use immune cells to treat illness. , ... the immunological equivalent of "neighborhood police" specialized squads ... organ, instead of an entire city, the body. , ... Louis have shown that the liver, skin and uterus ...
(Date:4/17/2014)... of The Proceedings of the National ... 29, raises a number of startling questions about a ... take for granted. At the end of the last ... shifted from hunting animals and gathering fruits and tubers ... straightforward and yet the more scientists learn, the more ...
(Date:4/16/2014)... artisanal green sea turtle fishery has uncovered a stark ... what may have become an unsustainable take, according to ... of Florida. , During the research period, conservation scientists ... between 1991 and 2011, with catch rates peaking in ...
Breaking Biology News(10 mins):Some immune cells defend only 1 organ 2Genetic study tackles mystery of slow plant domestications 2Genetic study tackles mystery of slow plant domestications 3Genetic study tackles mystery of slow plant domestications 4Declining catch rates in Caribbean green turtle fishery may be result of overfishing 2Declining catch rates in Caribbean green turtle fishery may be result of overfishing 3
... Rice University have developed a lithium-ion battery that can ... rechargeable battery created in the lab of Rice materials ... the components in a traditional battery. The research appears ... Scientific Reports . "This means traditional packaging for ...
... Douglas C. Wallace, PhD, a pioneering genetics researcher who ... receive the 2012 Genetics Prize of The Gruber Foundation. ... for his groundbreaking achievements in helping science understand the ... of disease and as markers for human evolution., He ...
... tap into endogenous, highly conserved and specific catalytic ... they have the potential to enable the development ... considered un-druggable by conventional small molecule and biologics ... been hindered by the challenges encountered by identifying ...
Cached Biology News:Rice researchers develop paintable battery 2Rice researchers develop paintable battery 3$500,000 Gruber Foundation Genetics Prize goes to Philadelphia scientist 2Oligonucleotide Delivery: Biology, Engineering and Development Conference 2Oligonucleotide Delivery: Biology, Engineering and Development Conference 3
Request Info...
Guinea Pig Complement...
Collected from 8-12 week-old New Zealand or Californian rabbits....
Enables rapid purification of double-stranded DNA fragments = 200 bp, including, for example, PCR reaction products, DNA fragments obtained in restriction enzyme digests, or double-stranded cDNA...
Biology Products: